Litcius/Paper detail

Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy

Zecong Xiao, Yitong Tan, Yujun Cai, Jinsheng Huang, Xiaobin Wang, Bo Li, Liteng Lin, Yong Wang, Xintao Shuai, Kangshun Zhu

2023Journal of Controlled Release39 citationsDOIOpen Access PDF

Abstract

The dense extracellular matrix (ECM) is a key barrier to tumor infiltration of cytotoxic T lymphocytes (CTLs), which greatly compromises T cell-dependent immunotherapy of hepatocellular carcinoma (HCC). Herein, hyaluronidase (HAase), IL-12, and anti-PD-L1 antibody (αPD-L1) were co-delivered using a pH and MMP-2 dual-sensitive polymer/calcium phosphate (CaP) hybrid nanocarrier. The dissolution of CaP triggered by tumor acidity facilitated the release of IL-12 and HAase responsible for ECM digestion, enhancing the tumor infiltration and proliferation of CTLs. Furthermore, the in situ-released αPD-L1 inside tumor, as triggered by an overexpressed MMP-2, prevented the tumor cell from escaping the killing effects of CTLs. Such combination strategy induced a robust antitumor immunity for efficiently suppressing HCC growth in mice. Additionally, tumor acidity-sheddable polyethylene glycol (PEG) coating enhanced the tumor accumulation of nanocarrier and reduced the immune-related adverse events (irAEs) induced by on-target off-tumor αPD-L1. This dual-sensitive nanodrug demonstrates an effective immunotherapy paradigm for other dense ECM-characterized solid tumors.

Topics & Concepts

ImmunotherapyCancer immunotherapyNanocarriersChemistryCancer researchExtracellular matrixTumor microenvironmentInfiltration (HVAC)Cytotoxic T cellImmune systemImmunologyMedicineMaterials scienceDrug deliveryBiochemistryComposite materialOrganic chemistryIn vitroCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesNanoplatforms for cancer theranostics